AD/PD 2022 | Immunotherapy in treating Alzheimer’s disease

Beka Solomon, PhD, Tel Aviv University, Tev Aviv, Israel, discusses immunotherapy in treating Alzheimer’s disease (AD). Prof. Solomon compares healthy individuals to individuals afflicted by AD – stating that natural levels of antibodies against amyloid-β are different between them, suggesting that due to AD patients not having necessary antibodies, immunotherapy could replace the antibodies which could not be developed. This is an excellent opportunity for immunotherapy to help those with AD, yet it could also target neuroinflammation when combined with other treatments. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.